Trial Profile
Real-World, observational, retrospective cohort study evaluating effects and safety of Pirfenidone in Idiopathic Pulmonary Fibrosis patients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Aug 2019
Price :
$35
*
At a glance
- Drugs Pirfenidone (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms IRENE
- 13 Aug 2019 Results assessing effectiveness of pirfenidone over 12 months administered according to clinical practice in a large cohort of Italian patients with IPF published in the Respiratory Medicine
- 30 Nov 2018 New trial record
- 14 Nov 2018 Results presented at the 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research